

APPENDIX 19: ECONOMIC PLAN

This document identifies the priorities for economic analysis and the proposed methods for addressing these questions as described in section 7.1.3 of the Guidelines Manual (2009).

1.1 GUIDELINE

Title of guideline: Psychosis in conjunction with substance misuse: the assessment and management of psychosis with substance misuse

1.2 PROCESS FOR AGREEMENT

The economic plan was prepared by the guideline economist in consultation with the rest of the NCC technical team and GDG. It was discussed and agreed on 11/09/2009 by the following people¹

For the NCC and GDG:	
NCC economist:	Matthew Dyer
NCC representative(s) ² :	Tim Kendall, Katherine Leggett, Laura Shields, Craig Whittington
GDG representative(s) ³ :	Peter Tyrer
For NICE:	
CCP lead ⁴ :	Tim Stokes
Commissioning manager:	Claire Turner
Economic lead ⁵ :	Francis Ruiz, Stefanie Kinsley
Costing lead:	Brian Sloan

Proposals for any substantive changes will be circulated by email to this group. If revisions are agreed, they will be listed as addenda to this document (section 5 below).

¹This may be done by face-to-face meeting, teleconference, or email as convenient.

² May be the project manager, a systematic reviewer or research fellow and/or the centre director or manager, as appropriate for the NCC and guideline.

³ May be GDG chair, clinical lead and/or other members as appropriate.

⁴ CCP Director or Associate Director who is taking the lead for the guideline.

⁵ One of the CCP health economic Technical Advisors.

1.3 PROPOSED ECONOMIC PLAN

Clinical Question (in PICO format if possible)		Requires analysis ⁶	Comment and explanation
Assessment/screening			
1	How should we identify people with coexisting psychosis and substance misuse?	Medium priority for analysis	<p>Identification of people with coexisting psychosis and substance misuse may have important resource implications in terms of influencing the downstream cost effectiveness of interventions directed to this specific population. However, identification and assessment of people with coexisting psychosis and substance misuse is likely to involve a combination of various physical, biological, psychological and neuropsychiatric measures. Modelling the care pathway from assessment to patient stratification and potential complications of harmful substance misuse would require significant resources in order to identify appropriate data relating to the effectiveness of assessment and monitoring tools as well as of the interventions for the clinical management of complications. Furthermore, it is unlikely that the literature will provide sensitivity and specificity data relating to all possible combinations in order to populate an economic model.</p> <p>Alternative methods of screening/identification may be analysed in an economic model depending on the clinical data available. If this is not possible, the GDG will consider undertaking simple cost analyses to assess the total costs and any potential savings associated with alternative screening and identification tools.</p> <p>For all methods of screening/identification, resource implications as well as any implementation issues will be considered by the GDG when making recommendations.</p>
2	In people with coexisting psychosis and substance	Not relevant	This question is not relevant for economic analysis as it addresses the key

- ⁶
- a **'Not relevant'**: questions where economic analysis is not appropriate (e.g. about definitions, prognosis or information needs for patient);
 - b **'In literature'**: questions where high-quality, recent and relevant economic evaluations are already available;
 - c **'High priority for analysis'**: questions where an economic analysis is planned (important implications and analysis is thought to be feasible);
 - d **'Medium priority for analysis'**: questions where an economic analysis may be done (less important implications or questions over feasibility);
 - e **'Low priority for analysis'**: questions where economic analysis could be done, but the expected impact on outcomes and NHS resources is low.

	misuse, what are the key elements for a comprehensive assessment (of needs and risks)?		elements that are necessary in assessing people with coexisting psychosis and substance misuse rather than alternative assessment strategies themselves, which may have important resource implications.
Models of care/access to services			
3	In people with coexisting psychosis and substance misuse, does an integrated model of care (usually involving the model of assertive community treatment) when compared with an alternative management strategy lead to improved outcomes?	High priority for analysis	Identifying the most (cost) effective model of care for people with coexisting psychosis and substance misuse has important resource use implications. There is some existing economic evidence which will be presented to the GDG ¹⁻³ . Depending on the available clinical data, an economic model will be developed to assess the cost-effectiveness of an integrated model of care in comparison other management strategies including serial or parallel models of care. The relative clinical efficacy of alternative management strategies will be dependent on the guideline systematic review and meta-analyses. If there is no clinical data available to compare the effectiveness of alternative management strategies, simple cost analyses will be conducted.
4	In people with coexisting psychosis and substance misuse, do the psychological/psychosocial interventions listed below (delivered within an integrated service model) when compared to an alternative management strategy lead to improved outcomes? individual interventions group interventions family interventions contingency management residential treatment (with/without recovery model) combined interventions	High priority for <u>separate</u> analysis	Effective psychological/psychosocial interventions will be included as part of the economic analysis for question 3 where appropriate clinical data allows direct or indirect comparisons between such interventions for this population. There is some existing economic evidence which will be presented to the GDG ⁴⁻⁶ . The relative clinical efficacy of alternative psychological/psychosocial interventions will be dependent on the guideline systematic review and meta-analyses. If there is no available data to allow comparison between psychological/psychosocial interventions, then comparisons of the cost-effectiveness of individual interventions versus standard care will be made. Again this is dependent on availability of relevant data and time constraints. If this is not possible, the GDG will consider simple cost analyses to assess costs and potential savings associated with specific interventions that are judged by the GDG to be associated with important resource implications. For all interventions that are analysed, resource implications as well as implementation issues (e.g. availability of appropriately trained staff in the NHS) will be considered by the GDG when making recommendations.
5	In people with coexisting psychosis and substance misuse, does staffed accommodation when compared to an alternative management strategy lead to improved outcomes?	Low priority for analysis	Staffed accommodation for people with coexisting psychosis and substance misuse has resource implications. However, this topic is considered a low priority for further analysis as it is unlikely there will be sufficient quantitative clinical evidence to inform a de novo economic model.

Inpatient care/residential rehabilitation			
6	When a person with coexisting psychosis and substance misuse is admitted to an inpatient mental health setting (including forensic settings), should treatment follow the same principles as interventions delivered in a community setting? Sub-question: Are there subgroups of people for whom we would alter our approach to treatment?	Not relevant	This clinical question is not a suitable topic for economic analysis as it does not seek to directly compare the (clinical) effectiveness/efficacy of inpatient mental health care versus community mental health care for people with coexisting psychosis and substance misuse. Instead, the question is addressing whether treatment follows the same underlying general principles in both inpatient and community health care settings.
Care pathways			
7	In people with coexisting psychosis and substance misuse, what is the most appropriate care pathway (involving all NHS and non-NHS providers) and referral guidance at each transition?	Low priority for analysis	Identifying appropriate care pathways for people with coexisting psychosis and substance misuse may have important resource implications (both within and outside of the NHS and PSS settings). However, this topic is considered a low priority for further analysis as it is unlikely there will be sufficient quantitative clinical evidence to inform a de novo economic model. However, for all care pathways that are discussed by the GDG, resource implications as well as implementation issues (e.g. availability of appropriately trained staff in the NHS) will be considered by the GDG when making recommendations.
Medication for psychosis			
8	For people with coexisting psychosis and substance misuse, should the medical treatment of their psychosis be modified as a result of the substance misuse problem and the treatment provided? During the acute phase During non-acute care If so, how should treatment be modified?	Medium priority for analysis	Pharmacological interventions for people with psychosis will have important resource implications. If the clinical evidence suggests that such interventions are to be modified (during the acute or non-acute phase) for people with coexisting substance misuse, it will be important to analyse their relative cost-effectiveness. However, it is unlikely that there will be adequate clinical evidence on specific pharmacological treatments for people with psychosis <u>and</u> coexisting substance misuse in order to inform a de novo economic model. Consideration will also be given to the cost-effectiveness of pharmacological interventions analysed in previously published guidelines from the NCCMH on Bipolar Disorder; Drug Misuse (opioid detoxification) and Schizophrenia ⁷⁻⁹ . The GDG will also consider resource implications when making relevant recommendations.
Psychological/psychosocial interventions for psychosis			
9	For people with coexisting psychosis and	Medium	Psychological/psychosocial interventions for people with psychosis will have

	<p>substance misuse, should the psychological/ psychosocial treatment of their psychosis be modified as a result of the substance misuse problem and the treatment provided?</p> <p>During the acute phase During non-acute care</p> <p>If so, how should treatment be modified?</p>	<p>priority for analysis</p>	<p>important resource implications. If the clinical evidence suggests that such interventions are to be modified (during the acute or non-acute phase) for people with coexisting substance misuse, it will be important to analyse their relative cost-effectiveness.</p> <p>However, it is unlikely that there will be adequate clinical evidence on specific psychological/ psychosocial treatments for people with psychosis <u>and</u> coexisting substance misuse in order to inform a de novo economic model. Consideration will also be given to the cost-effectiveness of pharmacological interventions analysed in previously published guidelines from the NCCMH on Bipolar Disorder; Drug Misuse (psychological interventions) and Schizophrenia ^{7,9,10}. The GDG will also consider resource implications when making relevant recommendations.</p>
Medication/physical interventions for substance misuse			
10	<p>For people with coexisting psychosis and substance misuse, should the medical/physical treatment of substance misuse be modified as a result of the presence of psychosis and the treatment provided?</p> <p>During the acute phase During non-acute care</p> <p>If so, how should treatment be modified?</p>	<p>Medium priority for analysis</p>	<p>Medical/physical treatments for people with substance misuse will have important resource implications. If the clinical evidence suggests that such interventions are to be modified (during the acute or non-acute phase) for people with coexisting substance misuse, it will be important to analyse their relative cost-effectiveness.</p> <p>However, it is unlikely that there will be adequate clinical evidence on specific medical/physical interventions for people with psychosis <u>and</u> coexisting substance misuse in order to inform a de novo economic model. Consideration will also be given to the cost-effectiveness of pharmacological interventions analysed in previously published guidelines from the NCCMH on Bipolar Disorder; Drug Misuse (opioid detoxification) and Schizophrenia ⁷⁻⁹. The GDG will also consider resource implications when making relevant recommendations.</p>
Psychological/psychosocial interventions for substance misuse			
11	<p>For people with coexisting psychosis and substance misuse, should the psychological/ psychosocial treatment of substance misuse be modified as a result of the presence of psychosis and the treatment provided?</p> <p>During the acute phase</p>	<p>Medium priority for analysis</p>	<p>Psychological/ psychosocial interventions for people with substance misuse will have important resource implications. If the clinical evidence suggests that such interventions are to be modified (during the acute or non-acute phase) for people with coexisting substance misuse, it will be important to analyse their relative cost-effectiveness.</p> <p>However, it is unlikely that there will be adequate clinical evidence on specific psychological/ psychosocial interventions for people with psychosis <u>and</u> coexisting substance misuse in order to inform a de novo economic model.</p>

	During non-acute care If so, how should treatment be modified?		Consideration will also be given to the cost-effectiveness of pharmacological interventions analysed in previously published guidelines from the NCCMH on Bipolar Disorder; Drug Misuse (psychological interventions) and Schizophrenia 7;9;10. The GDG will also consider resource implications when making relevant recommendations.
Drug interactions			
12	In people with psychosis and substance misuse, is there any evidence that the management of drug interactions or adverse effects from pharmacological treatments should be different from those people without coexisting disorders? If so, how should management of drug interactions be modified?	Low priority for analysis	This is a low priority for economic analysis as it does not directly address the comparative clinical effectiveness of specific pharmacological treatments for people with coexisting psychosis and substance misuse. Furthermore, it is unlikely that there will be sufficient evidence on drug interactions within people with co-existing psychosis and substance misuse.

For each question where economic analysis is proposed:

Question number(s) ⁷	Outline proposed method of analysis ⁸
3, 4	<p data-bbox="427 353 1321 409">Integrated care model compared with alternative management strategies in people with coexisting psychosis and substance misuse.</p> <p data-bbox="427 450 1358 539">An economic model, most likely in the form of decision tree, will be developed to assess the cost effectiveness of alternative management strategies for people with coexisting psychosis and substance misuse.</p> <p data-bbox="427 580 1358 804">The key comparators considered for analysis will be an integrated care model (usually involving the model of assertive community treatment) along with serial or parallel models of care. The comparators will be determined by the availability of clinical data. Alternative models of care will be considered if appropriate clinical data allow direct or indirect comparisons between them. The study population will be people with coexisting psychosis and substance misuse.</p> <p data-bbox="427 844 1378 1001">The main health states in the model are expected to be relapse/no relapse (measured as exacerbation of symptoms requiring change in health care management). Other possible important outcomes that may be considered in the model include: impact on mortality/physical morbidity and; impact on substance misuse.</p> <p data-bbox="427 1041 1378 1176">The time horizon of the analysis will depend on the availability of data (endpoints of relevant RCTs), but will ideally be long enough to consider the full impact on costs and outcomes associated with response/ remission as a result of alternative [patient] management strategies.</p> <p data-bbox="427 1216 1378 1440">An NHS and Personal Social Services (PSS) perspective will be taken for the analysis. Resource use involved in the management strategies will be based on clinical studies (RCTs or observational studies) reporting relevant data, Hospital Episode Statistics (HES)⁹ for England, other published literature and, where evidence is lacking, GDG expert opinion. Unit costs will be taken from national sources (BNF, NHS reference costs, PSSRU Health and Social Care Costs) where possible (BMA, 2007; DH 2008; Curtis, 2008).</p> <p data-bbox="427 1480 1378 1664">If possible, outcomes will be expressed in the form of QALYs. If not, studies reporting utilities specific to people with coexisting psychosis and substance misuse, it may be possible to refer to studies reporting utility scores derived in people with psychosis or substance misuse alone. Secondary outcomes, such as the number of people responding to treatment or in remission at the endpoint of analysis may also be considered.</p>

⁷ Two or more questions may be addressed by a single analysis if appropriate.

⁸ Give a brief description of the type of analysis that is proposed, as far as is known at this stage. Consider the type of economic evaluation (CEA, CUA, CCA,...); how outcomes will be measured (QALYs, LYS,...); the type of modelling (decision tree, Markov, simulation...); proposed comparators and population subgroups to be considered; potential sources of information and assumptions; and whether analysis could be based on an existing model. Follow methods advised in the Guidelines Manual whenever possible. Note that this is not expected to be a full project protocol, and that the methods of analysis may change.

⁹ www.hesonline.nhs.uk

	<p>Costs and outcomes will be discounted at a rate of 3.5 if the time horizon of the model is beyond 12 months (with rates of between 0-6% to be used in sensitivity analyses).</p> <p>Deterministic and probabilistic sensitivity analyses will be used to explore the impact of uncertainty in key parameters on the results of the analysis. Several studies have explored the cost-effectiveness of alternative management strategies for people with co-existing psychosis and substance misuse (Clark, 1998; Craig, 2008; Weaver, 2009). These will be reviewed and a summary of their key findings presented to the GDG. Studies of adequate quality and relevance will be included in GRADE profiles developed for clinical and health economics evidence.</p> <p>Psychological/psychosocial interventions (delivered within an integrated service model) compared with alternative management strategies An economic model, most likely in the form of decision tree, will be developed to assess the cost effectiveness of psychological/psychosocial interventions for people with coexisting psychosis and substance misuse.</p> <p>The key comparators considered for analysis will be individual interventions including CBT or motivational interviewing (MI); group interventions including CBT or MI; family interventions; contingency management; residential treatment; and combined interventions. The comparators will be determined by the availability of clinical data. Alternative psychological/psychosocial interventions will be considered if appropriate clinical data allow direct or indirect comparisons between them.</p> <p>The study population will be people with coexisting psychosis and substance misuse. The main health states in the model are expected to be relapse/no relapse (measured as exacerbation of symptoms requiring change in health care management). Other possible important outcomes that may be considered in the model include: impact on mortality/physical morbidity and; impact on substance misuse.</p> <p>The time horizon of the analysis will depend on the availability of data (endpoints of relevant RCTs), but will ideally be long enough to consider the full impact on costs and outcomes associated with response/ remission as a result of alternative [patient] management strategies.</p> <p>An NHS and Personal Social Services (PSS) perspective will be taken for the analysis. Resource use involved in the management strategies will be based on clinical studies (RCTs or observational studies) reporting relevant data, Hospital Episode Statistics (HES)¹⁰ for England, other published literature and, where evidence is lacking, GDG expert opinion. Unit costs will be taken from national sources (BNF, NHS reference costs, PSSRU Health and Social Care Costs ¹¹⁻¹³) where possible (BMA, 2007; DH 2008; Curtis, 2008).</p> <p>If possible, outcomes will be expressed in the form of QALYs. If not, studies reporting utilities specific to people with coexisting psychosis and substance misuse, it may be possible to refer to studies reporting utility scores derived in people with psychosis or substance misuse alone. Secondary outcomes, such as</p>
--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

¹⁰ www.hesonline.nhs.uk

	<p>the number of people responding to treatment or in remission at the endpoint of analysis may also be considered.</p> <p>Costs and outcomes will be discounted at a rate of 3.5% if the time horizon of the model is beyond 12 months. Discount rates will be altered between a plausible range of 0-6% in sensitivity analyses of costs and outcomes.</p> <p>Deterministic and probabilistic sensitivity analyses will be used to explore the impact of uncertainty in key parameters on the results of the analysis. Several studies have explored the cost-effectiveness of psychological/psychosocial interventions for people with co-existing psychosis and substance misuse (Haddock, 2003; Jerrell, 1994; Johnson, 2000). These will be reviewed and a summary of their key findings presented to the GDG. Studies of adequate quality and relevance will be included in 'economic profiles' specifically developed for clinical and health economics evidence.</p>
--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Key references

Clark, R. (1998) Cost-Effectiveness of Assertive Community Treatment versus Standard Case Management for Persons with Co-occurring Severe Mental Illness and Substance Use Disorders. *Health Services Research*, 33, 1285-1308.

Craig, T.K.J., Johnson, S., McCrone, P., *et al.* (2008) Integrated care for co-occurring disorders: Psychiatric symptoms, social functioning, and service costs at 18 months. *Psychiatric Services*, 59, 276-282.

Weaver, M. (2009) Cost-Effectiveness Analysis of Integrated Care for People with HIV, Chronic Mental Illness and Substance Abuse Disorders. *Journal of Mental Health Policy and Economics*, 12, 33-46.

Haddock, G., Barrowclough, C., TARRIER, N., *et al.* (2003) Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse - 18-month outcomes of a randomised controlled trial (Structured abstract). *British Journal of Psychiatry*, 183, 418-426.

Jerrell, J., Hu, T.W. & Ridgely, M.S. (1994) Cost-effectiveness of substance disorder interventions for people with severe mental illness. *Journal of Mental Health Administration*, 21, 94-297.

Johnson, J. (2000) Cost-effectiveness of mental health services for persons with a dual diagnosis: A literature review and the CCMHCP. *Journal of Substance Abuse Treatment*, 18, 100-127.

National Collaborating Centre for Mental Health (2010) *Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Updated)*. Leicester: The British Psychological Society and the Royal College of Psychiatrists.

National Collaborating Centre for Mental Health (2008) *Drug misuse: psychosocial interventions*. Leicester: The British Psychological Society and the Royal College of Psychiatrists.

National Collaborating Centre for Mental Health. (2008). *Drug misuse: Opioid detoxification*. Leicester: The British Psychological Society and the Royal College of Psychiatrists.

National Collaborating Centre for Mental Health. (2006) *Bipolar Disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care*. Leicester: The British Psychological Society and the Royal College of Psychiatrists.

British Medical Association and the Royal Pharmaceutical Society of Great Britain (2007) *British National Formulary 54*. London: Pharmaceutical Press.

Department of Health (2008) *NHS reference costs 2006-07*. London: Department of Health.

Curtis, L. (2007) *Unit costs of health and social care*. Canterbury: Personal Social Services Research Unit, University of Kent

Addenda to economic plan

The following substantive revisions to the plans set out in section 3 above have been agreed.

Date	Question number(s)	Agreed change to number or type of analyses